Forteo vs Tymlos
Side-by-side cost comparison based on Medicare Part D data
Forteo
Teriparatide
Manufactured by Eli Lilly
Tymlos
Abaloparatide
Manufactured by Radius Health
Forteo costs 27% less per claim than Tymlos ($1,337.00 vs $1,839.00). A generic version of Forteo is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Forteo | Tymlos |
|---|---|---|
| Avg Cost Per Claim | $1,337.00 | $1,839.00 |
| Total Medicare Spending | $567.0M | $456.0M |
| Total Beneficiaries | 48,000 | 28,000 |
| Total Claims | 424,000 | 248,000 |
| Annual Cost/Patient | $11,813.00 | $16,286.00 |
| Year-over-Year Change | -18.4% | +14.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Eli Lilly | Radius Health |
| Condition | Osteoporosis | Osteoporosis |
| Generic Name | Teriparatide | Abaloparatide |
Forteo vs Tymlos: What the Data Shows
Forteo (Teriparatide) and Tymlos (Abaloparatide) are both used to treat osteoporosis. Based on Medicare Part D data, Forteo costs $1,337.00 per claim, which is 27% less than Tymlos at $1,839.00 per claim.
Medicare spent $567.0M on Forteo and $456.0M on Tymlos. In terms of patient reach, Forteo serves more beneficiaries (48,000 vs 28,000).
Year-over-year spending changed -18.4% for Forteo and +14.6% for Tymlos. Tymlos saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Forteo is cheaper at $1,337.00 per claim, compared to $1,839.00 for Tymlos. That makes Forteo about 27% less expensive per claim based on Medicare Part D data.
Yes, both Forteo and Tymlos are used to treat osteoporosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Teriparatide and generic Abaloparatide can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Forteo covering 48,000 beneficiaries, and $456.0M on Tymlos covering 28,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.